Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Kras
    (1)
  • MEK
    (1)
  • Ras
    (1)
  • Target Protein Ligand-Linker Conjugate
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

target/Ras/1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    3
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
K-Ras ligand-Linker Conjugate 6 formate
T212098
K-Rasligand-Linker Conjugate 6 formate includes a target protein K-Ras ligand (K-Ras recruitment motif) and a PROTAC linker, capable of recruiting E3 ligases such as VHL, CRBN, MDM2, and IAP. It is utilized in synthesizing PROTACK-Ras Degrader-1, a potent PROTACK-Ras degrader, achieving a K-Ras degradation rate of ≥70% in SW1573.
  • Inquiry Price
Inquiry
Size
QTY
(2Z,3Z)-U0126
T69826218601-62-8
(2Z,3Z)-U0126 is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase. It was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with IC50 of 72 nM for MEK1 and 58 nM for MEK2. U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase and mammalian target of rapamycin pathways.
  • $1,520
6-8 weeks
Size
QTY
BBO-8520
BBO8520
T858092893809-51-1
BBO-8520 is a first-in-class, direct dual inhibitor of both the active (ON) and inactive (OFF) conformational states of KRASG12C. BBO-8520 binds to the Switch-II/Helix3 pocket of KRASG12C, covalently modifying the target cysteine residue and thereby disabling effector binding in the ON state. BBO-8520 exhibits potent inhibition of KRAS signaling under growth factor-activated conditions, where existing OFF-only inhibitors demonstrate minimal activity. In vivo, BBO-8520 rapidly engages its target and suppresses signaling, resulting in durable tumor regression across multiple models, including those resistant to OFF-only KRASG12C inhibitors.
  • $424
In Stock
Size
QTY